Denise Myshko

Investigators have identified the lowest dose of the immunosuppressive ATG needed to preserve beta cells in newly diagnosed children with Type 1 diabetes with the lowest side effects.

Increasing the cholesterol-lowering protein ApoM in mice improved retinal health and may be the key to slowing age-related macular degeneration in its earliest stages.

Brian K. Lee, Ph.D., of Drexel University Dornsife School of Public Health, says that despite the fact that some studies suggest there is link between acetaminophen use during pregnancy and neurodevelopmental disorders, there is a lack of evidence to support that conclusion.

Optum Rx has increased brand drug reimbursement minimums for 2,300 independent pharmacies that are not its network.

A new study has found that caffeine and other substances can influence gene regulation in Escherichia coli bacteria, making them more resistant to antibiotics.

Former CDC director Susan Monarez, Ph.D., testified at today’s Senate hearing that HHS Secretary Robert F. Kennedy Jr. directed her to fire scientists for refusing to rubber-stamp vaccine changes.

Providers also have concerns about being able to stock certain medications, which would have a negative impact on their patients, according the Avalere Health survey.

The NIH is funding a new study at Weill Cornell that aims to identify the regulatory roles of gene variants involved in Type 1 diabetes development.

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher risks of liver transplant and death among treated patients.

CT-155, a smartphone-based prescription digital therapeutic, addresses an unmet need in schizophrenia, showing safety and efficacy in a phase 3 trial.

Two separate analyses in Health Affairs find the One Big Beautiful Bill creates a loophole that exempts or delays orphan drugs — many of them blockbuster drugs that generate billions of dollars in sales — from price negotiations.

ICER’s comparative effectiveness and value review of Wegovy, Zepbound and oral semaglutide finds they are highly effective treatments with significant health benefits, but affordability and long-term management are still unresolved.

Panelists at a session at the Pharmacy Benefit Management Institute’s annual meeting in Orlando discussed how stop-loss insurance addresses rising costs from cell therapies, oncology treatments, and orphan drugs affecting self-funded employer plans.

At the PBMI annual meeting, experts warned that soaring prices for new cancer therapies require greater data sharing, precision medicine and value-based contracts to ensure patients get access to effective treatments without overwhelming costs.

IQVIA’s Scott Briggs forecasts increased GLP-1 drug spending, limited biosimilar savings and patient adherence hurdles for novel therapies at the Pharmacy Benefit Management Institute’s annual meeting in Orlando.

Employers face rising healthcare costs and specialty drug challenges, prompting a shift towards strategic partnerships with PBMs for better solutions, according to Karen van Caulil, Ph.D., president and CEO of the Florida Alliance for Healthcare Value, who chatted with MHE in the final installment of a two-part video interview.

Employers are demanding more transparency and partnership from pharmacy benefit managers (PBMs), according to Karen van Caulil, Ph.D., president and CEO of the Florida Alliance for Healthcare Value, who spoke with MHE ahead of her remarks at the Pharmacy Benefit Management Institute’s annual meeting in Orlando.

New approaches are needed to manage the costs, access and adherence issues related to the GLP-1 drugs, say panelists at the Pharmacy Benefit Management Institute’s annual meeting in Orlando.

Pharmacy and medical benefit programs have traditionally operated separately, despite having similarities. Nishi Goel, Pharm.D., vice president of customer experience, Agadia, is trying to change that.

The growing trend of at-home drug administration emphasizes the need for integrated medical and pharmacy reviews, according to Nishi Goel, Pharm.D., vice president of customer experience, Agadia.

Bildyos and Bilprevda have the same indications as the reference products Prolia and Xgeva and are expected to be available later this year.

Leqembi IQLIK, a subcutaneous version of Leqembi, will launch on Oct. 6, 2025, with a list price of $375 per autoinjector.

Researchers suggest that access to treatment and socioeconomic resources can influence glycemic control and disparities in the management of patients with Type 1 diabetes.

Cadisegliatin acts in the liver to increase the activity of glucokinase, an enzyme that plays a role in regulating blood glucose levels.

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with nutrition and lifestyle support, as well as prescriptions for medications.

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of 2025, with diabetes submissions to follow in 2026.

A new Business Group on Health survey finds that nearly a quarter of all employer healthcare spending (24%) went to pharmacy expenses in 2024, and employers forecast an 11% to 12% increase in pharmacy costs heading into 2026.

Dawnzera (donidalorsen) will be available in a few days with a list price of $57,462 per dose

The FDA has granted priority review of the sNDA and assigned a goal date of Dec. 20, 2025, for Imcivree to treat patients with acquired hypothalamic obesity, which is caused by an abnormality of the hypothalamus.

A new study finds Medicare beneficiaries are facing higher deductibles and cost-sharing requirements following changes implemented by health plans as a result of the Inflation Reduction Act.